Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)

Inclusion Criteria: * Male or female patients aged greater than or equal to 18 years. * Diagnosis of type 2 diabetes as defined by WHO criteria. * Type 2 diabetes treated with insulin for at least 3 months (insulin dose of at least 30 U/day for at least 4 weeks). * HbA1C greater than or equal to 7%. * Having signed the informed consent form. Exclusion Criteria: General: * Weight loss \> 5 kg within 3 months prior to screening visit. * Pregnancy or lactation. * Absence of medically approved contraceptive methods for females of childbearing potential. * Administration of other investigational drugs within 30 days prior to screening visit. * Previous participation in a Rimonabant study. * Presence or history of allergic reaction or intolerance to multiple drugs. Related to endocrine and metabolic disorders: * Presence of any clinically significant endocrine disease according to the Investigator.Note: euthyroid patients on replacement therapy will be included if the dosage of thyroxine is stable for at least 3 months prior to screening visit. * Fasting C-peptide \< 1.0 ng/mL. Related to other disorders: * Presence of any severe medical or psychological condition that in the opinion of the Investigator would compromise the patient's safety or successful participation in the study. * Presence or history of cancer within the past 5 years with the exception of adequately treated localized basal cell skin cancer or in situ uterine cervical cancer. Related to laboratory findings: * Positive test for hepatitis B surface antigen and/or hepatitis C antibody. * Abnormal TSH level (TSH \> ULN or \< LLN). * Positive urine pregnancy test. Related to previous or concomitant medications: * Antidiabetic drugs other than insulin within 3 months prior to screening visit. * Drugs affecting weight (e.g., sibutramine, orlistat, herbal preparations, etc).